The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2023 | Molecular testing for the evaluation of colorectal cancer
Jennifer Rachel Eads, MD, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, comments on current molecular testing protocols in colorectal cancer. Testing for RAS and DNA mismatch repair mutations are the standard in colorectal cancer. Dr Eads additionally talks about the need to increase HER2 testing, where an increase in anti-HER2 therapies are becoming more available to patients. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
